WILLIAM HANDY: Open Payments
NPI 1124017744 · ABINGDON, VA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,148 in 63 payments from 21 companies in 2025. Trend: 2023 $137 · 2024 $672 · 2025 $1,148
Food & beverage: $1,148
| Company | Payments | Amount |
|---|---|---|
| Lilly USA, LLC | 7 | $188 |
| ABBVIE INC. | 14 | $157 |
| Novartis Pharmaceuticals Corporation | 5 | $111 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 5 | $91 |
| Esperion Therapeutics, Inc. | 5 | $85 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $64 |
| Abbott Laboratories | 3 | $58 |
| Novo Nordisk Inc | 1 | $50 |
| Alkermes, Inc. | 2 | $42 |
| Axsome Therapeutics, Inc. | 2 | $36 |
Products named: ZEPBOUND, LEQVIO, CAPLYTA, NEXLETOL, VRAYLAR, TRINTELLIX, FREESTYLE LIBRE 3, QULIPTA.
Industry payments across VA — which companies pay providers there.
